Showing results (781-790 of 2,556) with videos related to
Sort By:
Pageof 256
Therapeutics and Clinical Risk Management|August 15, 2018
Management and outcomes of hyperparathyroidism: a case series from a single institution over two decadesHassan Al-Thani, Moamena El-Matbouly, Maryam Al-Sulaiti, et al.Therapeutics and Clinical Risk Management|September 4, 2018
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisalMarco Proietti, Giuseppe BorianiTherapeutics and Clinical Risk Management|May 2, 2018
Total hip arthroplasty and cardiovascular complications: a reviewAfshin Taheriazam, Amin Saeidinia, Faeze KeihanianTherapeutics and Clinical Risk Management|May 2, 2018
Safety study: is there a pathologic IGF-1, PDGF and TGF-β cytokine expression caused by adjunct BMP-7 in tibial and femoral non-union therapy?Christian Fischer, Christian Reiner, Gerhard Schmidmaier, et al.Therapeutics and Clinical Risk Management|May 2, 2018
Calcification score versus arterial stenosis grading: comparison of two CT-based methods for risk assessment of anastomotic leakage after esophagectomy and gastric pull-upDe-Hua Chang, Sebastian Brinkmann, Lucy Smith, et al.Therapeutics and Clinical Risk Management|September 2, 2025
Knowledge, Attitude, and Practice of Nurses in Preventing Complications in Patients with Nephrotic Syndrome: A Cross-Sectional StudyNannan Wang, Xueqin Deng, Ting Zhang, et al.Therapeutics and Clinical Risk Management|April 28, 2010
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisNora Koutruba, Jason Emer, Mark LebwohlTherapeutics and Clinical Risk Management|May 14, 2010
Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provisionCurtis L Cooper, Celine Giordano, Dave Mackie, et al.Therapeutics and Clinical Risk Management|August 30, 2008
Trabectedin and its potential in the treatment of soft tissue sarcomaPhilippe A Cassier, Armelle Dufresne, Jean-Yves Blay, et al.Therapeutics and Clinical Risk Management|August 30, 2008
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophyMischel G Neill, Rohan Shahani, Alexandre R ZlottaPageof 256